Health Care & Life Sciences » Biotechnology | Biotoxtech Co. Ltd.

Biotoxtech Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
555
4,894
3,711
1,160
1,176
Depreciation, Depletion & Amortization
1,870
1,766
1,652
1,522
1,897
Other Funds
5
960
2
77
34
Funds from Operations
522
1,180
410
5,051
4,778
Changes in Working Capital
740
867
1,208
233
1,247
Net Operating Cash Flow
218
2,047
798
5,283
6,024
Capital Expenditures
986
306
496
492
3,414
Sale of Fixed Assets & Businesses
-
12
1
2
5
Purchase/Sale of Investments
938
3,538
128
94
888
Net Investing Cash Flow
343
4,343
624
386
11,514
Issuance/Reduction of Debt, Net
3,300
546
614
687
1,900
Net Financing Cash Flow
3,296
6,335
612
227
2,166
Net Change in Cash
2,633
83
1,931
4,728
3,511
Free Cash Flow
884
2,350
1,278
4,810
2,615
Net Assets from Acquisitions
-
-
-
-
7,165
Other Sources
1,621
-
-
40
39
Change in Capital Stock
-
6,748
-
537
300
Exchange Rate Effect
103
27
104
58
187
Other Uses
51
500
-
31
91

About Biotoxtech Co.

View Profile
Address
Ochang Science Industrial Complex
Cheongju-si NC 28115
Korea, Republic Of
Employees -
Website http://www.biotoxtech.com
Updated 09/14/2018
Biotoxtech Co., Ltd. engages in the provision of non-clinical drugs trials. It operates through the following business divisions: Safety Evaluation Research Field, Efficacy Evaluation and Analysis Research Field. The Safety Evaluation Research Field offers studies such as general toxicity, local toxicity, reproductive and developmental, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology or hematology.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.